Results 181 to 190 of about 31,482 (296)

Evaluation of Discontinuation and Re‐Initiation of Biologic Therapies in Psoriasis: Real‐World Data

open access: yesInternational Journal of Dermatology, EarlyView.
The cumulative probability of remaining relapse‐free following biologic therapy discontinuation was 35.6%, 19%, 11.6%, and 9.1% at 6, 12, 18, and 24 months, respectively. Prolonged relapse durations were associated with a low baseline PASI score, the presence of a PASI 90 response at discontinuation, the absence of triggering factors, and the use of IL‐
Ahmet Taha Aydemir, Nihal Kundakcı
wiley   +1 more source

Aire and Fezf2 Shape the Medullary Thymic Epithelial Cell Immunopeptidome for Central Tolerance

open access: yesImmunology, EarlyView.
Central tolerance is shaped not merely by promiscuous gene expression in medullary thymic epithelial cells (mTECs), but by the subset of self‐peptides ultimately presented on MHC class II molecules. We propose a multilayered framework in which AIRE/Aire and FEZF2/Fezf2, together with specialised differentiation programmes—including thymic mimetic‐cell ...
Geraldo Aleixo Passos   +5 more
wiley   +1 more source

Aqueous Carbon Capture Using Guanidinium-Functionalized Hollow Fiber Sorbent Contactors. [PDF]

open access: yesJACS Au
Danielson MK   +14 more
europepmc   +1 more source

Soft‐Tissue Augmentation During Implant Placement in the Aesthetic Zone: Clinical, Radiographic, Histological and Patient‐Reported Outcomes From a Randomised Controlled Trial Using Connective Tissue Graft and a Volume‐Stable Collagen Matrix

open access: yesJournal of Clinical Periodontology, EarlyView.
ABSTRACT Aim To evaluate the clinical, radiographic, histological and patient‐reported outcome measures (PROMs) of soft‐tissue augmentation (STA) during implant placement in the aesthetic zone using a connective tissue graft (CTG) or a volume‐stable collagen matrix (VCMX). Materials and Methods In this three‐arm randomised controlled trial, 25 patients
Louiza Papantonatou   +4 more
wiley   +1 more source

Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Our findings show that greater proportions of litifilimab‐treated participants than placebo experienced 20%, 50%, 70% or 90% improvements in CLASI‐A score from baseline and CLASI‐A scores of 0–1 or 0–3. Similar results were observed using physician global assessments, supporting the Phase 2 LILAC study primary analysis in CLE.
Victoria P. Werth   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy